Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors
December 13 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the
appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of
Directors.
“Dr. Barlow’s expertise in market access and commercial pricing
will be invaluable as we continue to develop our pipeline of novel
autoimmune therapeutics,” said Craig Wheeler, President and Chief
Executive Officer at Momenta Pharmaceuticals. “We are honored to
bring Dr. Barlow onto our Board and look forward to leveraging her
industry insight as we embark on pre-commercial strategic planning
for our potential immune-mediated disease therapies.”
“It is a privilege to join Momenta’s Board at an important time
in the Company’s evolution developing novel drug candidates,” adds
Dr. Jane F. Barlow. “I look forward to working closely with the
dedicated team behind a strong portfolio to advise on effective
market access strategy moving forward.”
Dr. Barlow is currently the Chief Executive Officer of Jane
Barlow & Associates, LLC, Executive Vice President and Chief
Clinical Officer at Real Endpoints, and Board Director at
TherapeuticsMD. Prior to her current roles, she was Associate Chief
Medical Officer at CVS Health and Chief Medical Officer of CVS
Health’s Government Services arm where she successfully implemented
industry-leading clinical strategies. Formerly, she served as Vice
President of Clinical Innovation at MEDCO Health Solutions. Dr.
Barlow has extensive experience in steering pharmaceutical
development by strategically weighing the value and economic costs
that drug candidates bring to the healthcare ecosystem at large.
Focusing on cost-effective outcomes, she is dedicated to developing
innovative medical and pharmaceutical access strategies.
Dr. Barlow received her medical degree from Creighton University
School of Medicine and subsequently completed her residency in
occupational and environmental medicine at The Johns Hopkins
University, where she also earned her M.P.H. She is a distinguished
graduate of the United States Air Force School of Aerospace
Medicine and served as Chief of Flight Medicine at the Beale and
Maxwell Air Force Bases. Additionally, she holds an M.B.A. from the
University of Alabama. Accompanying her board-certification in
occupational medicine, she is a fellow of the American College of
Occupational and Environmental Medicine and the American College of
Preventive Medicine. She is a diplomat of the American College of
Physician Executives and a member of the American Medical
Association.
About Momenta
Momenta Pharmaceuticals is a biotechnology company with a
validated innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases and advancing its late stage biosimilar portfolio. The
company is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit
the website at www.momentapharma.com, which does not form a part of
this press release.
The Company’s logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward-Looking Statements
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or
prospects, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including but not
limited to statements about the timing of regulatory approval
and launch of our product candidates; development timelines and
strategies; the Company’s ability to meet its development and
strategic goals; hypotheses regarding certain actions and effects
of our product candidates; market potential of our products
and product candidates; design, timing and goals of clinical trials
; the use, efficacy, safety, potency, tolerability, convenience and
commercial potential of our product candidates. Forward-looking
statements may be identified by words such as "believe,"
"continue," “plan to”, "potential," "will," and other similar words
or expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors, including
those referred to under the section "Risk Factors" in the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2019 filed with the Securities and Exchange Commission, as well as
other documents that may be filed by the Company from time to time
with the Securities and Exchange Commission. As a result of such
risks, uncertainties and factors, the Company's actual results may
differ materially from any future results, performance or
achievements discussed in or implied by the forward-looking
statements contained herein. The Company is providing the
information in this press release as of this date and assumes no
obligations to update the information included in this press
release or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
INVESTOR CONTACT: Patty Eisenhaur
Momenta
Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:Karen SharmaMacDougall
1-781-235-3060momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024